Starpharma (ASX:SPL) has signed a commercial arrangement for its antiviral nasal spray Viraleze in Vietnam with orders in excess of 2 million since late October.
The company said some orders have already been delivered with further product expected to be delivered in early 2022.
VIRALEZE launched in Vietnam last week, with the formal launch events attended by clinicians, healthcare professionals, politicians, and media representatives from over 30 news channels.
It is available in Vietnam to retail consumers, clinics, hospitals and pharmacies through local medical distribution networks.
Vietnam, which has a population of approximately 98 million, is experiencing a significant Delta outbreak with just over half of its population vaccinated.
Starpharma CEO Dr Jackie Fairley said, “We are delighted that the launch of VIRALEZE in Vietnam was so successful and has already generated significant sales.
"This demand is indicative of the significant need for products like VIRALEZE, which are complimentary to vaccines and other preventative strategies."
Starpharma’s distribution arrangement for VIRALEZE in Vietnam is with HealthCo Australia, with Truong Bao Land, and Nam Thanh Trade and Medical Services Company responsible for importation and distribution locally in Vietnam.
Starpharma said it continues negotiations with potential commercial partners elsewhere in multiple countries in Europe, Asia, and the Middle East.